We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

59 hedge funds and large institutions have $18.2M invested in Galectin Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

863% more call options, than puts

Call options by funds: $154K | Put options by funds: $16K

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

48% more capital invested

Capital invested by funds: $12.3M → $18.2M (+$5.92M)

0.34% more ownership

Funds ownership: 11.98% → 12.32% (+0.34%)

11% less funds holding

Funds holding: 66 → 59 (-7)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
59
Holders Change
-7
Holders Change %
-10.61%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
17
Reduced
10
Closed
11
Calls
$154K
Puts
$16K
Net Calls
+$138K
Net Calls Change
+$116K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$531K
2
WANY
Wealthspire Advisors (New York)
New York
+$406K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$99.8K
4
Squarepoint
Squarepoint
New York
+$90.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$72K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$351K
2
6CM
683 Capital Management
New York
-$184K
3
MML Investors Services
MML Investors Services
Massachusetts
-$90K
4
AWS
Atria Wealth Solutions
New York
-$66.2K
5
IAA
Independent Advisor Alliance
North Carolina
-$59.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
51
Barrett & Company
Rhode Island
$9.16K – – –
MAM
52
Meeder Asset Management
Ohio
$9.12K – – –
SIS
53
Sound Income Strategies
Florida
$7.12K – – –
JP Morgan Chase
54
JP Morgan Chase
New York
$4.47K +$91 +48 +3%
BFEC
55
Benjamin F. Edwards & Company
Missouri
$4K – – –
BCPWM
56
Bradley & Co Private Wealth Management
Florida
$2.39K – – –
Group One Trading
57
Group One Trading
Illinois
$1.29K +$1.02K +542 New
GRP
58
Global Retirement Partners
California
$598 – – –
SIC
59
Salem Investment Counselors
North Carolina
$400 – – –
6CM
60
683 Capital Management
New York
– -$184K -111,035 Closed
MML Investors Services
61
MML Investors Services
Massachusetts
– -$90K -54,227 Closed
IAA
62
Independent Advisor Alliance
North Carolina
– -$59.9K -36,100 Closed
AWM
63
AE Wealth Management
Kansas
– -$46.4K -26,841 Closed
BFM
64
Boothbay Fund Management
New York
– -$39.4K -23,749 Closed
Bank of New York Mellon
65
Bank of New York Mellon
New York
– -$38.3K -23,080 Closed
Citigroup
66
Citigroup
New York
– -$17.7K -10,650 Closed
GI
67
Gradient Investments
Minnesota
– -$6.31K -3,800 Closed
IA
68
IFP Advisors
Florida
– -$3.32K -2,000 Closed
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
– -$2K -1,069 Closed
UBS Group
70
UBS Group
Switzerland
– -$1.03K -622 Closed
1 2
3

GALT Hedge Fund Activity: Q1 2024 in Review

59 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2024, worth a combined $18.2M — up 48% from $12.3M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GALT and 4 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 17 added.

The largest buyer was Susquehanna International Group, adding an estimated $531K. The largest seller was Morgan Stanley, cutting an estimated $351K.

  • 59 institutional investors held Galectin Therapeutics (GALT) as of Q1 2024, down from 66 in Q4 2023.
  • Funds reported $18.2M of Galectin Therapeutics stock for Q1 2024, up 48% quarter-over-quarter.
  • 4 funds opened new Galectin Therapeutics positions in Q1 2024 and 11 closed out, a net change of -7 holders.
  • The largest Galectin Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $531K added.
  • The largest Galectin Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $351K sold.

Based on aggregated 13F filings for Q1 2024.